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Abstract: 
Major depression is associated with high burden, disability and costs. Non-adherence limits the 
effectiveness of antidepressants. Community pharmacists (CP) are in a privileged position to 
help patients cope with antidepressant treatment. The aim of the study was to evaluate the 
impact of a CP intervention on primary care patients who had initiated antidepressant 
treatment. Newly diagnosed primary care patients were randomised to usual care (UC) (92) or 
pharmacist intervention (87). Patients were followed up at 6 months and evaluated three 
times (Baseline, and at 3 and 6 months). Outcome measurements included clinical severity of 
depression (PHQ-9), health-related quality of life (HRQOL) (Euroqol-5D) and satisfaction with 
pharmacy care. Adherence was continuously registered from the computerised pharmacy 
records. Non-adherence was defined as refilling less than 80% of doses or having a medication-
free gap of more than 1 month. Patients in the intervention group were more likely to remain 
adherent at 3 and 6 month follow-up but the difference was not statistically significant. 
Patients in the intervention group showed greater statistically significant improvement in 
HRQOL compared with UC patients both in the main analysis and PP analyses. No statistically 
significant differences were observed in clinical symptoms or satisfaction with the pharmacy 
service. The results of our study indicate that a brief intervention in community pharmacies 
does not improve depressed patients’ adherence or clinical symptoms. This intervention 
helped patients to improve their HRQOL, which is an overall measure of patient status. 
Key words: 
Depressive Disorder; Medication Adherence; Antidepressive Agents; Pharmaceutical Services; 
Primary Health Care 
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1. Introduction 
Almost 13% of Europeans will suffer major depression at some point in their life (Alonso et al. 
2004). Depressive disorders are associated with considerable disability (Mathers and Loncar 
2006) and with increased suicide rates (Angst et al. 1999). This results in a high burden for 
patients and society and is costly to the system, mainly due to patients’ inability to work 
(Salvador-Carulla et al. 2011;Wade and Haring 2010). 
The detection, prevention and treatment of depression should improve to minimize relapse. 
Antidepressants decrease risk of relapse, especially in adherent patients (Geddes et al. 2003). 
Low adherence to antidepressants has been systematically reported (Lingam and Scott 2002) 
and, in primary care, largely explains low concordance of real practice with clinical guidelines 
for depression (Pinto-Meza et al. 2008).  
Community pharmacists (CPs) are easily accessible to ambulatory patients and can help 
improve adherence. A systematic review evaluating the effectiveness of pharmacist 
intervention in improving adherence to antidepressants identified six relevant studies (Rubio-
Valera et al. 2011). Although most of the individual studies had shown non-statistically 
significant results, when pooled, a statistically significant effect was observed favouring 
pharmacist intervention. The review included interventions conducted by pharmacists in 
hospital services and CPs and sub-group analyses showed that, when pooled separately, CPs 
studies produced non-statistically significant results. This sub-group analysis included only 3 
studies, implying that the power of the meta-analysis to detect differences may be limited. 
Only one of the studies had been conducted in a European country (Brook et al. 2005). In the 
per protocol (PP) analysis, Brook found that patients who received a CPI with an informative 
videotape showed better antidepressant adherence. It is not possible to isolate the relative 
impact of each intervention component. 
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The aim of the present study was to evaluate the effectiveness of a community pharmacist 
intervention (CPI) compared with usual care (UC) in improvement of adherence to 
antidepressants and patient wellbeing in a population initiating pharmacological treatment 
following diagnosis of depression by their general practitioner (GP). 
2. Experimental procedures 
2.1 Study Design 
This was a six-month follow-up naturalistic parallel-group controlled trial with random 
allocation of participants into UC and UC plus CPI. A detailed description of the study protocol 
has been provided elsewhere (Rubio-Valera et al. 2009). 
2.2 Participant recruitment and randomisation 
Participants were recruited at 4 Primary Care Health Centres (PCHC) (30 GPs) from two 
satellite towns in the Barcelona metropolitan area (Gavà and El Prat) (October 2008-May 
2011). At first, only the PCHC from Gavà participated in the study but to accelerate patient 
inclusion, a population from El Prat was included in March 2010. Eligible participants were 
patients aged between 18 and 75 who had been prescribed an antidepressant by a GP due to a 
depressive disorder. Patients who had taken any antidepressants or consulted a mental health 
specialist in the previous 2 months; those with a history of psychotic, bipolar disorder or drug 
abuse; and those with cognitive impairment, were not included.  
Spanish patients can choose any pharmacy countrywide to fill their prescription and can switch 
from one to another in successive visits. Patients were asked to refill their antidepressant 
prescriptions at the same pharmacy during the study. Those who agreed were included. 
GPs invited eligible patients to participate and obtained signed informed consent. To ensure 
allocation concealment, every GP received a set of 10 sequentially numbered, opaque, sealed 
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envelopes generated by an external investigator (MRV) containing patient assignment. 
Randomisation was generated at the patient level by a computerised random-number 
generator following a permuted block design (1:1). As patients were enrolled, the GP 
sequentially stapled one of the envelopes to the prescription. 
When the patient gave the prescription to their CP, the pharmacist opened the envelope and 
created a patient study chart distinguishing between UC and CPI groups. Interventions 
performed by the pharmacists, both in the UC and CPI groups, were recorded on the patient 
study chart. Blinding of participants and pharmacists was not possible but outcome assessors 
were blind to the allocation. Patients were asked to avoid discussing the study among them. 
2.3 Intervention 
All the pharmacies in the towns (39) were invited to participate but 6 declined; citing heavy 
workload (n=2) or lack of interest in the study (n=4). To homogenise the intervention, 
pharmacists received an 8-hour training session focused on implementation and information-
collection guidelines. Only 24 of the participating pharmacies were finally approached by 
patients and took part in the study (58 CPs). Two pharmacies dropped out: one because the 
pharmacy closed and one because the CP responsible for the study left. 
Patients received the CPI on visiting the pharmacy where they received their first prescription 
of the 6-month antidepressant course. The CPI consisted of an educational intervention 
centred on improving patients' knowledge of antidepressants and awareness of the 
importance of adherence. In patients with a sceptical attitude towards the medication, the 
intervention aimed to reduce stigma, reassure the patient about possible side-effects, and 
stress the importance of following GPs' advice.  
As patients were beginning treatment with antidepressants, the first contact was considered 
crucial. During the first visit, the pharmacist provided the patient with information about the 
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medicine and briefly discussed various aspects of the illness to improve understanding of the 
treatment, eliminate erroneous preconceptions and reinforce the concept of illness to the 
patient.  In subsequent visits, the pharmacist conducted a short review of some points covered 
in the first visit and checked patient progress (improvement, appearance of side-effects, or 
queries). First and subsequent contacts took a mean of 14.4 and 7.7 minutes, respectively.  
Control patients received UC from their GP and CP. UC varied from one pharmacy to another 
but mainly consisted of dispensing the medication; answering patients’ questions and giving 
some basic advice about how to take the medication.  First and subsequent visits took a mean 
of 7.8 and 7.7 minutes, respectively. 
2.4 Measurements 
Three assessments (baseline, 3 and 6 months) were conducted by 8 trained psychologists. 
Adherence to antidepressants was assessed using the computerised pharmacy records that 
registered all the information about medication in the patient’s clinical history at the time of 
purchase. Non-adherence was defined as refilling <80% of the prescribed doses; a definition 
that has a reasonable balance between sensitivity and specificity (Hansen et al. 2009) or having 
a treatment gap >1 month (Peterson et al. 2007). 
Clinical severity of depression was measured with the Patient Health Questionnaire, 9-item 
depression module (PHQ-9) (Kroenke et al. 2001;Spitzer et al. 1999).  
HRQOL was evaluated using the EuroQol-5D (EQ-5D) and Spanish tariffs or utility indexes were 
calculated (Badia et al. 1998, 1999;Dolan et al. 1995;The EuroQol Group 1990). 
Satisfaction with the pharmacist service was measured with a patient-satisfaction 
questionnaire (Armando et al. 2008). 
During recruitment, clinical diagnosis was made by the GP and, at the baseline assessment, 
was confirmed using the research version of the Structured Clinical Interview for DSM-IV Axis I 
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Disorders (SCID-I) (First et al. 1996, 1999). GPs were blind to the DSM-IV diagnosis and patient 
inclusion was performed according to their usual practice.  
Chronic physical conditions were assessed using a "yes" or "no" check-list.  
2.5 Sample size calculation and data analysis 
Sample size calculation was based on the main study objective (i.e. improving adherence to 
antidepressants). The sample size was calculated for an expected difference between groups 
of at least 17 points in the percentage of medication intake, which is in agreement with the 
study by Brook et al. 2005. It was estimated that a sample of 162 patients would have a power 
of 80% at a significance level of 5% to detect these differences.  There were no missing values 
for our main outcome. 
Pre-treatment comparability between groups was assessed applying the χ2-test or Fisher exact 
test for categorical data, the Student’s t-test for continuous variables and the non-parametric 
equality-of-medians test for biased numerical data. 
To evaluate intervention effectiveness, multilevel mixed-effects linear and logistic models 
were fitted that allowed the inclusion of all available data. A two-level longitudinal multilevel 
structure was used where observations were clustered within patients. The models predict 
treatment response using group as a fixed factor, time point (baseline, 3 and 6 months) as a 
within-participants repeated factor, and participants as a random factor. Models with variables 
not assessed at baseline (adherence and satisfaction) included only two time points. 
For the main analyses, all participants were included as randomised regardless of whether they 
received the intervention or had incomplete follow-up data. To deal with the problem of 
missing observations in longitudinal studies, it has been suggested that applying multilevel 
analysis is a good option. Multilevel analysis is very flexible in handling missing data and it has 
been shown that it is better to apply multilevel analysis to an incomplete dataset than applying 
imputation methods (Twisk 2006). Consequently, missing data was not imputed. 
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A second analysis was conducted according to the PP principle. Participants in the intervention 
group were excluded if they had never received the pharmacist intervention (never bought 
medication or did so at a non-participating pharmacy). Participants in the control group that 
never bought medication (i.e. did not receive usual pharmaceutical care) were also excluded 
from the PP analyses. 
The models were fitted using Restricted Maximum Likelihood. To account for correlation 
among several observations for each subject, an unstructured correlation matrix was used. In 
all models the gender and the interaction term ‘time*group’ were included in the model as 
covariates. When the interaction was significant in the model, the effect of the intervention 
was considered to vary during the course of the study (HRQOL models only). When this 
interaction term was not significant, the model without the interaction term was used.  
Other sociodemographic and clinical characteristics that could plausibly affect the outcome 
were tested using a likelihood ratio test (LR-test). We compared the models with and without 
these variables and included them if the LR-test was positive (p≤0.10). Number needed to treat 
(NNT) was calculated for the main outcome (adherence) by computing the inverse of the 
differences between groups in the probability of being adherent. For the continuous outcome 
variables showing statistically significant differences between groups, effect size (Cohen’s d) 
was calculated by means of standardised mean difference between the two populations using 
the pooled standard deviation of the two groups at baseline. The effect size was categorised as 
small (0.2), medium (0.5) and large (0.8) (Cohen 1988). 
All analyses were conducted with STATA 11.0. 
3. Results 
3.1 Participants and drop-outs 
Figure 1 shows the study flow chart. A total of 234 patients were referred by the GPs. Finally, 
179 patients were randomised to UC (92) and CPI (87), were evaluated at baseline and 
included in the main analysis. Only 87 (95%) and 64 (74%) in the control and intervention 
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group, respectively, received the intervention as allocated and were included in the PP 
analysis. 
All assessment visits were completed by 120 (67%) patients. Nineteen (11%) participants were 
only evaluated at baseline. Forty (23%) patients missed 1 follow-up assessment (7 at 3-months 
and 33 at 6-months) because they could not be contacted or refused to attend.  
-Figure 1- 
3.2 Baseline data 
Table 1 shows the participants’ baseline characteristics. Most participants were women 
(75.4%), with mean age of 46.6 years. Fifty-one percent of the participants met DSM-IV criteria 
for major depression. The mean baseline severity of depression (PHQ-9) was 15.9 (moderately 
severe symptoms). Differences existed in the proportion of women between groups; all 
analyses were adjusted for gender. 
-Table 1- 
3.3 Adherence to antidepressants 
Table 2 shows the patients’ probability of remaining adherent, models-based mean 
satisfaction, severity of depression and HRQOL. Table 3 shows the regression models for 
adherence and satisfaction.  
Eleven (6%) patients never bought medication (non-initiators) and a high proportion of 
patients discontinued at 3 (48.0%) and 6-month follow-up (57.0%).  
In the main analyses, CPI group patients seemed more likely to remain adherent both at 3 
(67.7% vs 83.3%) and 6-month (46.3% vs 67.3%) follow-up (Table 2) but the trend did not 
reach statistical significance (OR=2.24; p=0.209) (Table 3). 
In the per PP analysis, the same trend was observed (Table 2) and differences between groups 
were close to statistical significance but did not reach it (OR=3.44; p=0.055) (Table 3). NNT was 
5, indicating that to prevent non-adherence in one patient, we needed to implement the 
intervention in 5 (Table 2). 
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-Table 2- 
-Table 3- 
3.4 Satisfaction with pharmacy service 
Overall, patient satisfaction with the pharmacy service was high in both groups. No differences 
were observed between groups at 3 or 6 months (Tables 2 and 3). 
3.5 Clinical severity of depression 
Both groups showed an improvement in symptoms at 3 and 6 months (Table 2). Table 4 shows 
the depression severity regression models (PHQ-9) and HRQOL. No differences in symptom 
severity were observed between groups (Table 4). 
3.6 HRQOL 
Figure 2 shows the multilevel-based mean utilities (EQ-5D tariffs) and the improvement in 
HRQOL in the control and intervention groups. 
In both analyses, a significant time*group interaction was found in EQ-5D tariffs in favour of 
the intervention group (Table 4). Overall improvement was higher in the intervention group in 
both the main (0.25 vs 0.14) and PP (0.27 vs 0.16) analyses. The effect size was small to 
medium in both analyses (0.31 and 0.33 respectively). 
-Figure 2- 
4. Discussion 
CPI group patients tend to have a higher probability of remaining adherent at 3 and 6 months 
than those receiving UC. In the PP analysis, this result did not quite reach statistical 
significance (p=0.055). However, the difference was clinically relevant since the NNT was 
relatively small for a fairly quick, easy-to-implement intervention (intervention implementation 
needed in 4 patients in order to help one extra patient to remain adherent at 3 and 6-month 
follow-up). One possible reason for not achieving statistical significance would be a lack of 
statistical power. The large amount of drop-outs and patients not following study protocol 
could have reduced the study power. Furthermore, we did not take into account the clustering 
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effect of the multilevel mixed-effects analyses when the sample size was calculated, which 
could have limited our capacity to detect differences between groups.  
In general, our study results are consistent with those of Brook 2005 and Rickles 2006. In the 
intent-to-treat analysis, between-group differences were not found although these studies did 
observe statistically significant adherence differences between groups in the PP analysis. Both 
studies used a protocol that considered exclusively those patients that had received a 
minimum of 3 pharmacist contact sessions. Nevertheless, those patients who received one (or 
two) interventions before abandoning the medication may not have wanted to receive a 
second (or third) intervention session. Consequently, intervention group patients who 
abandoned the medication early may have been excluded from the PP analysis so increasing 
the difference between groups. As such, there may be some difficulty in generalizing from this 
result.  
In our case, first patient contact was crucial and demanded a more flexible protocol 
stipulation.  
Despite having detected statistically significant differences in the degree of adherence to 
antidepressants, none of the previous studies found differences in clinical improvement (Adler 
et al. 2004;Brook et al. 2005;Capoccia et al. 2004;Finley et al. 2003;Rickles et al. 2006). 
However, a powerful meta-regression based on collaborative care in depression showed a 
positive association between improved adherence and improvement in depressive 
symptomatology (Bower et al. 2006). The lack of difference in clinical improvement could 
imply that its relationship with adherence is not as direct as it may appear and is affected by 
diverse factors such as pharmacological efficacy or other environmental or social elements. 
Another factor could be diagnostic accuracy, as only half the patients met major depression 
SCID criteria and antidepressants have only shown an effect on moderate to severe major 
depression. This could explain the lack of correlation between adherence and clinical 
outcomes. The analysis performed on the major-depression patient subsample (SCID) showed 
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no statistically significant differences between groups (data available on request), although 
this study was not designed to observe differences in this population and the power of the 
study was insufficient to draw conclusions on subsample behaviour. 
In contrast to Capoccia 2004, statistically significant HRQOL differences between groups were 
observed, indicating that patients who received extra pharmacy care perceived improved 
HRQOL. Effect size was small to moderate, which led us to question the clinical relevance of 
this difference. It could be due to placebo effect or desirability bias. Nevertheless, both groups 
showed very high levels of pharmacy-service satisfaction with no statistically significant 
differences between groups. As part of the intervention, the pharmacist discussed the nature 
of the treatment and illness with the patient. This may have helped the patient to cope with 
the new diagnosis, reducing stigmatization and even, in some cases, modifying inappropriate 
health beliefs. This could manifest itself as an improvement in self-perception with respect to 
HRQOL (the constructs of quality of mental life). 
Although not directly related to intervention, we observed a high proportion of non-initiators 
(around 6%). These patients had agreed to participate in a study to improve the use of 
antidepressants and, as such, we concluded that the proportion of non-initiators would be 
much higher in normal practice. In previous studies, non-initiation rates reached 15% (Bull et 
al. 2002). We consider that non-initiators motives require detailed study. 
This study had a number of limitations. Firstly, enrollment may have been biased against 
patients unwilling to take antidepressants. However, the figures regarding treatment 
discontinuation correspond to those found previously in Catalonia (Serna et al. 2010) and we 
conclude that our sample can be extrapolated to the primary care population. 
Secondly, inclusion criteria were very broad which may have created great variability among 
subjects, although this did favour generalisation of the results and the study’s external validity. 
Third, the pharmacists attended both UC and CPI patients, which could have led to some 
contamination. This could have been prevented by performing a cluster randomisation at the 
13 
 
pharmacy level.  The pharmacists were asked to exercise great care and to register the 
intervention carried out on control patients. Also, although they were asked not to share 
information with other participants, patients could have transmitted information among 
themselves.  
Fourth, only 74% of intervention group patients received at least one pharmacy intervention 
and this may have limited its impact and affected the power to detect differences. 
Fifth, patients could change pharmacy in successive visits. Consequently, even those patients 
who received the intervention attended very few sessions. However, this leads us to believe 
that even with a single, relatively simple, although slightly more intense, intervention applied 
at the point of initiating the medication, we can obtain significant improvements in adherence 
and patients’ HRQOL; although this would require further exploration.  
Sixth, as a result of the financial crisis, shortly after study commencement, a series of 
economic adjustments were made which affected the viability of pharmacies in Catalonia 
(Spanish Resolution 2008-2010). In addition, the low incidence of new cases meant that the 
inclusion period had to be extended. These two factors, taken together, may have 
demotivated and/or exhausted our pharmacists. This may be reflected in the results although 
the pharmacists recorded the interventions carried out and, as such, we believe that the 
impact was minimal. 
Finally, the use of pharmacy registers as a measure of adherence involves a series of 
limitations. Patients may acquire the tablets but not take them and this measure does not 
provide us with information with respect to the time of taking the medication or reasons for 
non-adherence. However, it showed relatively good agreement with electronic pill container, 
especially in depressed patients (Hansen et al. 2009). Moreover, this measure allowed us to 
collect information without the patient being aware that he or she was being assessed even 
when the patients did not keep their evaluation appointments. Consequently, we had no 
missing data in our main study variable. 
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Despite all these limitations, this study is the first performed in Europe which focuses 
specifically on a community pharmaceutical intervention to improve adherence to 
antidepressants. In addition, it represents the largest study sample of patients undertaking a 
community pharmacy intervention. In spite of being low, adherence to the protocol is higher 
than that reported in previous studies (Brook et al. 2002). Finally, the naturalistic nature of the 
study design benefited the results external validity.  
The study results indicate that a brief intervention in community pharmacy is not effective in 
improving patients’ adherence to antidepressants or clinical symptomatology. Though not 
statistically significant, there was a clinically important improvement in the degree of 
adherence in the intervention group. Furthermore, this type of intervention does help patients 
with a new depressive episode to improve their HRQOL. As such, we believe that further 
studies are required to investigate the pharmaceutical intervention’s active components with 
the aim of increasing the impact on improvements in quality of life. The greatest limitation on 
the CPI was the lack of continuity in the service. We would recommend designing a single but 
more intensive intervention to be applied at the beginning of the treatment, making a greater 
effort to attempt to modify patients’ health concepts and beliefs about the treatment and the 
disease. Motivations for non-initiation of the treatment with antidepressants should be 
assessed in order to develop interventions that may be helpful in the recovery of these 
patients. 
Figure legends 
Figure 1. Study flow chart 
Figure 2. Multilevel based mean utility and overall improvement in the EQ-5D (95% CI) at 3 and 
6 month follow-up for the main and PP analyses 
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Table 1. Sample socio-demographic and clinical baseline characteristics 
 Usual care 
(n=92) 
Pharmacist’s 
intervention 
(n=87) 
P-value 
Gender(% women (n)) 83.7% (77) 66.7% (58) 0.008 
Age (mean (95% CI)) 46.3 (43.3, 49.2) 46.9 (44.0, 48.6) 0.742 
Marital status (% (n))   0.881 
Never married 14.1% (13) 18.4% (16)  
Married or living with someone 64.1% (59) 59.8% (52)  
Previously married 10.9% (10) 10.3% (9)  
Widow 10.9% (10) 11.5% (10)  
Education(% (n))   0.676 
No studies 7.6% (7) 5.8% (5)  
Primary 22.8% (21) 23.0%(20)  
Graduated 23.9% (22) 19.5% (17)  
Secondary 26.1% (24) 31.0% (27)  
University 19.6% (18) 19.0% (34)  
Other − 2.3% (2)  
Working status((% (n))   0.493 
Househusband/housewife 13.0% (12) 17.2% (15)  
Paid employment 40.2% (37) 29.9% (26)  
Paid employment but on sick 
leave 
21.7% (20) 24.1% (21)  
Unemployed 17.4% (16) 16.1% (14)  
Retired 7.6% (7) 9.2% (8)  
Other − 2.3% (2)  
NS/NC ( Missing)  1.2% (1)  
Clinical severity according to 
PHQ-9(mean (95% CI)) 
15.8 (14.6, 16.9) 16.1 (14.7, 17.4) 0.776 
Number of co-morbidities(% of 
cases over the median 
(median=3) (n)) 
37.0% (34) 40.2% (35) 0.653 
 
Table 2. Multilevel model-based probabilities of remaining adherent and multilevel model-based mean satisfaction and severity of depression at 3 
and 6 month follow-up in the control and intervention groups for the main analysis and PP analyses 
 Main analysis   PP   
 Baseline 3-months 6-months Baseline 3-months 6-months 
Probability of remaining adherent(95% CI) and number needed to treat (NNT)¥ 
Usual Care NA 61.9% (26.4, 88.1) 40.2% (12.9, 75.3) NA 43.8%(15.7, 76.5) 25.7% (7.4, 59.8) 
Intervention NA 78.4% (48.0, 93.5) 60.1% (28.4, 85.11) NA 72.9% (41.7, 91.0) 54.4% (24.6, 81.4) 
NNT  6.1 5.0  3.4 3.5 
Mean satisfaction (95% CI)§ 
Usual Care NA 38.3 (32.8, 43.8) 39.0 (33.4, 44.5) NA 37.5 (31.4, 43.6) 37.9 (31.8, 44.0) 
Intervention NA 40.1 (35.1, 45.1) 40.8 (35.7, 45.8) NA 39.2 (33.4, 44.9) 39.6 (33.8, 45.4) 
Mean severity of depression (95% CI)П    
Usual Care 14.0 (12.3, 15.6) 6.8 (5.2, 8.5) 5.0 (3.2, 6.7) 14.0 (12.3, 15.8) 7.1 (5.2, 8.9) 5.1 (3.2, 7.0) 
Intervention 14.5 (13.0, 15.9) 7.4 (5.8, 8.9) 5.5 (3.9, 7.1) 14.8 (13.1, 16.4) 7.8 (6.1, 9.5) 5.9 (4.1, 7.6) 
NA=Not applicable 
¥Values for male patients of age 45.5 with a baseline severity of depressive symptoms of 16 (moderately-severe symptoms). 
§Values for male patients of age 45.5,never married and without comorbidities 
П Values for male patients of age 45.5 
Table 3. Multilevel model-based odds ratio (95% confidence interval) and p-values of the variables included in the models for adherence to 
antidepressants. 
&Constant or reference value corresponds to male patients of age 45.5 in the control group at baseline and with a baseline severity of 
depressive symptoms of 16 (moderately-severe symptoms) in the model for adherence and to never-marriedmale patients of age 45.5 without 
comorbidities in the control group at baseline in the model for satisfaction. 
ÇCentered in the median. One-year or 1-point increase. 
ni = variables not included in the model (negative LR-test). 
 Adherence to antidepressants (Odds Ratio (95% CI) and 
P-value) 
Satisfaction with the pharmacy service (β coefficients 
(95% CI) and P-value) 
 Main analysis PP analysis Main analysis PP analysis 
Constant& 1.63 (0.36, 7.37) 0.529 0.78 (0.19, 3.26) 0.734 38.3 (32.8, 43.8) 0.001 37.5 (31.4, 43.6) 0.001 
Group         
Control Reference  Reference  Reference  Reference  
Intervention 2.24 (0.64, 8.60) 0.209 3.44 (0.97, 12.22) 0.055 1.8 (-0.9, 4.5) 0.20 1.7 (-1.3, 4.7) 0.270 
Gender         
Men Reference  Reference  Reference  Reference  
Women 0.37 (0.08, 1.63) 0.188 1.21 (0.29, 4.97) 0.796 -1.2 (-4.6, 2.2) 0.48 -1.8 (-5.6, 1.9) 0.339 
AgeÇ 1.06 (1.01, 1.11) 0.013 1.04 (1.00, 1.09) 0.070 0.03 (-0.1, 0.2) 0.70 -0.02 (-0.2, 0.1) 0.849 
Time         
3-months Reference  Reference  Reference  Reference  
6-months 0.41 (0.21, 0.83) 0.012 0.44 (0.22, 0.90) 0.024 0.7 (-1.1,2.5) 0.45 0.4 (-1.6, 2.4) 0.673 
Depression baseline 
severity(PHQ9)Ç 
0.99 (0.89, 1.11) 0.911 0.98 (0.88, 1.09) 0.708 ni  ni  
Comorbidities  ni  ni  0.9 (0.3, 1.5) 0.01 0.8 (-5.6, 1.9) 0.339 
Marital status         
Never married ni  ni  Reference  Reference  
Married ni  ni  2.7 (-1.7, 7.2) 0.23 4.8 (-0.3, 9.9) 0.065 
Divorced ni  ni  2.7 (-3.0, 8.5) 0.35 4.5 (-2.0, 11.0) 0.178 
Widow ni  ni  -5.1 (-11.9, 1.7) 0.14 -2.4 (-9.8, 5.0) 0.529 
Table 4. Multilevel model based β-coefficients (95% confidence interval) and p-values of the variables included in the models for clinical 
severity of depression and health-related quality of life. 
 Severity of depressive symptoms (PHQ-9)* Health related quality of life (EuroQol-5D tariffs)* 
 Main analysis  PP analysis  Main analysis  PP analysis  
Constant& 13.95 (12.33, 15.58) 0.001 14.0 (12.27, 15.78) 0.001 0.67 (0.59, 0.74) 0.001 0.66 (0.58, 0.75) 0.001 
Group         
Usual Care Reference  Reference  Reference  Reference  
Intervention 0.51 (-0.77, 1.79) 0.432 0.77 (-0.67, 2.21) 0.297 -0.061 (-0.14, 0.01) 0.108 -0.09 (-0.17, -0.01) 0.038 
Gender         
Male Reference  Reference  Reference  Reference  
Female 2.37 (0.85, 3.89) 0.002 2.19 (0.49, 3.89) 0.011 -0.031 (-0.10, 0.04) 0.386 -0.031 (-0.11, 0.05) 0.438 
AgeÇ -0.04 (-0.09, 0.003) 0.067 -0.03 (-0.08, 0.02) 0.237 -0.003 (-0.01,  -0.00) 0.008 -0.003 (-0.01,  -0.00) 0.005 
Time         
Baseline Reference  Reference  Reference  Reference  
3-months -7.12 (-8.21, -6.03) 0.001 -7.0 (-8.1, -5.8) 0.001 0.133 (0.07−0.20) 0.001 0.13 (0.07, 0.20) 0.001 
6-months -9.00 (-10.17, -7.80) 0.001 -8.9 (-10.2, -7.7) 0.001 0.142 (0.08−0.21) 0.001 0.16 (0.09, 0.23) 0.001 
Depression 
baseline severity 
(PHQ-9)Ç 
ni  ni  -0.012 (-0.02−-0.01) 0.001 -0.01 (-0.02, -0.01) 0.001 
TimexGroupintera
ction 
        
Baseline     Reference  Reference  
Intervention group 
at 3-months 
ni  ni  0.06 (-0.03, 0.15) 0.204 0.07 (-0.03, 0.17) 0.145 
Intervention group 
at 6-months 
ni  ni  0.10 (0.01, 0.20) 0.034 0.11 (0.004, 0.22) 0.042 
&Constant or reference value corresponds to male patients of age 45.5 in the control group at baseline in the PHQ-9 model and to male 
patients of age 45.5 in the control group and with a baseline severity of depressive symptoms of 16 (moderately-severe symptoms) in the 
EuroQol-5D model. 
ÇCentered in the median. One-year or 1-point increase. 
ni = variables not included in the model 
Assessed for eligibility (n=234)
Excluded (n=55)
Not meeting inclusion criteria (n=11)
Substance abuse (n=6)
Age over 75 (n=1)
Psychotic or bipolar disorder (n=2)
ADs had not been prescribed (n=1)
Consulting a psychologist in the past 2 months (n=1)
Declined to participate (n=44)
Allocated to intervention group (n=87)
Received allocated intervention (n=64)
Did not receive allocated intervention (n=23)
(decided not to take antidepressants) (n=6)
(not identified as study participants when 
bought the medication) (n=17)
Allocated to control group (n=92)
Received usual care as intended (n=87)
Did not receive usual care as intended (n=5)
(decided not to take antidepressants) (n=5)
Randomized (n=179)
Analysed by intent-to-treat (n=87)
Analysed per protocol (n=64)
Analysed by intent-to-treat (n=92)
Analysed per protocol (n=87)
Analysis
Lost to follow-up (n=26)
Refused to attend to follow-up interview (n=16)
Were unable to contact (n=10)
Lost to follow-up (n= 26) 
Refused to attend to follow-up interview (n=16)
Were unable to contact (n=10)
Follow-up
0 80
0,85
0,90
0 65
0,70
0,75
,
0 50
0,55
0,60
,
,
Baseline 3‐monMain analysis
Usual care 0.66 (0.59, 0.74)  0.80 (0.72
Intervention 0.60 (0.53, 0.67)  0.79 (0.72
0,80
0,85
0,90
0,65
0,70
0,75
0,50
0,55
0,60
Baseline 3‐monPP analysis
Usual care 0.66 (0.58, 0.75) 0.79 (0.71
Intervention 0.58 (0.50, 0.65) 0.78 (0.70
Usual care
Intervention
ths 6‐months Overall improvement 
, 0.88)  0.81 (0.72, 0.89)  0.14 (0.08, 0.21) 
, 0.89)  0.85 (0.77, 0.93)  0.25 (0.18, 0.31) 
Usual care
Intervention
Overall
ths 6‐months  improvement 
, 0.88) 0.82 (0.74, 0.91) 0.16 (0.09, 0.23)
, 0.86) 0.85 (0.76, 0.93) 0.27 (0.19, 0.35)
